tislelizumab
novartis,beigene
['truce-02', 'nmibc', 'tislelizumab', 'mibc']
truce-02: phase ii study of tislelizumab combined with nab-paclitaxel for high-risk nmibc. #asco22 
Medical Oncologist - Urologic Oncology. Hospital Universitario La Paz - IdiPAZ, Madrid